anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Biliary tract cancer arises from the epithelial cells of the bile ducts. Until nowadays, no standard second-line treatment has been established following recurrence from the first-line treatment. Angiogenesis plays a key role in the carcinogenesis and development of biliary tract adenocarcinoma. Studies have shown that VEGF is expressed in more than 50% of biliary tract adenocarcinoma, and microvessel density is significantly associated with tumor progression, metastasis, and prognosis. Fruquintinib (trade name: Elunate) is a novel small molecule tyrosine kinase inhibitor. It is currently being evaluated in clinical trials for multiple cancers including lung cancer, gastric cancer and colorectal cancer and showed strong anti-tumor activity. The aim of the study is to evaluate the efficacy and safety of fruquintinib for patients with advanced or metastatic biliary tract adenocarcinoma who failed first-line chemotherapy.

The trial is a prospective, multicenter, single-arm design study. Eligible participants with advanced or metastatic biliary tract adenocarcinoma who have failed first-line chemotherapy with gemcitabine, platinum/S-1, and albumin paclitaxel. The study will explore the efficacy and safety of second-line treatment with fruquintinib, and quality of life during treatment. Tumor assessment was performed every 8 weeks as defined by RECIST 1.1. Blood samples will be collected at baseline (before treatment) and 2 weeks after treatment, and cfDNA will be collected for gene detection analysis to evaluate the correlation between different gene mutations and their changes and efficacy.
Systems and methods for providing assistance to a surgeon for minimizing errors during a surgical procedure are disclosed. A method includes creating a Three-Dimensional (3D) model of a patient using at least one image of an affected area of the patient. Surgical paths are retrieved for performing a surgical procedure. A surgical path, selected by a surgeon, may be displayed as overlaid on the 3D model. A haptic barrier and a hard barrier may be defined for different types of tissues and feedbacks may be associated with the haptic barrier and the hard barrier. Position of a surgical tool of a robotic surgical system may be monitored in real-time during a surgical procedure. Movement of the surgical tool into one of the haptic barrier and the hard barrier may be detected and a suitable feedback may be provided, based on the movement.
Polycystic ovary syndrome (PCOS) affects 8-13% of women. It is a multifaceted condition characterized by chronic anovulation and excess ovarian activity.

Since last decade, Clinical Reproductive Medicine Management System/Electronic Medical Record Cohort Database (CCRM/EMRCD) has been used in Reproductive Medical Center, First Affiliated Hospital of Zhengzhou University, and Henan Province Key Laboratory for Reproduction and Genetics. Information of patients (POI, PCOS, Endometriosis, azoospermia, ect) were recorded comprehensively. The current project plans to recruit PCOS participants in our center. Biological samples, questionnaires and short/long term health data will be collected. The study is aimed to provide evidence for PCOS prognosis.
Aspects and features relate to a system that transparently connects point of care testing (POCT) devices with electronic health records associated with a remote Laboratory Information System (LIS) to report test results in real-time or near real-time. The POCT results can be received from a POCT device at the mobile computing device. The mobile computing device and POCT device are located outside the LIS environment, for example, at a physician's office or remote clinic. The mobile computing device can use its own data proxy to configure low-level instrument protocol data from the POCT device for protected transmission over the wide area network infrastructure. POCT results can then be received in an LIS environment and provided to the LIS for transparently populating an Electronic Medical Record (EMR) with the POCT results. In some examples, the LIS or hospital information system can also update the point-of-care EMR.
Non-structural protein 3 (Nsp3) is the largest protein encoded by the coronavirus (CoV) genome. It consists of multiple domains that perform critical functions during the viral life cycle. CoV-Y is the most C-terminal domain of Nsp3, and it exhibits evolutionary conservation across diverse CoVs; however, the exact biological function of CoV-Y remains unclear. Here, we determined the crystal structure of CoV-Y of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Nsp3 using the single-wavelength anomalous diffraction method. We revealed the interaction between CoV-Y and the host BRCA1-associated protein (BRAP) using immunoprecipitation-mass spectrometry experiments. This interaction was subsequently confirmed in cellular assays, and the precise binding-regions between these two proteins were clarified. We found that this interaction is conserved in SARS-CoV and Middle East respiratory syndrome coronavirus. Next, we demonstrated that CoV-Y enhances IκBα and IκBβ phosphorylation and promotes the nuclear translocation of the downstream NF-κB members p50 and p65 through binding to BRAP. The CoV-Y-BRAP interaction can upregulate the transcript levels of the host inflammatory cytokines. Overall, our findings illustrate the biological function of CoV-Y for the first time and provide novel insights into coronavirus regulation of host inflammatory responses, as well as a possible target for antiviral drug development.
MBI will be performed in 25 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. Patients will then be instructed to consume 8-16 fluid oz of Ensure (350-700 calories). At 30 minutes after consumption of the meal, patients will receive a second injection of 4-6 mCi Tc-99m sestamibi and a repeat MBI study will be performed.
AIMS: Traditional atrial fibrillation (AF) recurrence after catheter ablation is reported as a binary outcome. However, a paradigm shift towards a more granular definition, considering arrhythmic or symptomatic burden, is emerging. We hypothesize that ablation reduces AF burden independently of conventional recurrence status in patients with persistent AF, correlating with symptom burden reduction.
METHODS AND RESULTS: Ninety-eight patients with persistent AF from the DECAAF II trial with pre-ablation follow-up were included. Patients recorded daily single-lead electrocardiogram (ECG) strips, defining AF burden as the proportion of AF days among total submitted ECG days. The primary outcome was atrial arrhythmia recurrence. The AF severity scale was administered pre-ablation and at 12 months post-ablation. At follow-up, 69 patients had atrial arrhythmia recurrence and 29 remained in sinus rhythm. These patients were categorized into a recurrence (n = 69) and a no-recurrence group (n = 29). Both groups had similar baseline characteristics, but recurrence patients were older (P = 0.005), had a higher prevalence of hyperlipidaemia (P = 0.007), and had a larger left atrial (LA) volume (P = 0.01). There was a reduction in AF burden in the recurrence group when compared with their pre-ablation burden (65 vs. 15%, P < 0.0001). Utah Stage 4 fibrosis and diabetes predicted less improvement in AF burden. The symptom severity score at 12 months post-ablation was significantly reduced compared with the pre-ablation score in the recurrence group, and there was a significant correlation between the reduction in symptom severity score and the reduction in AF burden (R = 0.39, P = 0.001).
CONCLUSION: Catheter ablation reduces AF burden, irrespective of arrhythmia recurrence post-procedure. There is a strong correlation between AF burden reduction and symptom improvement post-ablation. Notably, elevated LA fibrosis impedes AF burden decrease following catheter ablation.
The invention relates to an immunomodulating synbiotic composition comprising an active formula based on a probiotic component of live cells of a biologically pure culture of a bacterial strain selected from the group of Lactobacillus delbrueckii subsp. bulgaricus LLB-06-NBIMCC 8918, Lactobacillus helveticus LLH-108-NBIMCC 8760, Lactobacillus acidophilus LLA-10-NBIMCC 8242, Lactobacillus rhamnosus LLR-L1-NBIMCC 8769 and Lactobacillus fermentum LLF-01-NBIMCC 8781 or combinations thereof,or the prebiotic- Siberian larch bark (Larix gmelinii) and colostrum rich in proline-containing peptides and IgG at the amounts described in mg. The present invention also relates to a probiotic bacterial composition with immunomodulating action, comprising an effective amount of live cells of a biologically pure culture of a bacterial strain selected from the group of: Lactobacillus delbrueckii subsp. bulgaricus LLB-06-NBIMCC 8918, Lactobacillus helveticus LLH-108-NBIMCC 8760, Lactobacillus acidophilus LLA-10-N NBIMCC 8242, Lactobacillus rhamnosus LLR-L1-NBIMCC 8769, Lactobacillus fermentum LLF-01-NBIMCC 8781 or combinations thereof at the amounts described in mg according to the present invention, as well as to the bacterial strain Lactobacillus fermentum LLF-01 NBIMCC № 8781 and the strain Lactobacillus delbrueckii subsp. bulgaricus LLB-06 NBIMCC 8918 that produce bacterial composition with immunomodulating action. The compositions, according to the present invention, are intended for the preparation of a food supplement and / or a pharmaceutical product for the prevention and / or concomitant therapy of inflammatory and immune diseases of the gastrointestinal tract (immunomodulator at the level of mucosal immune system and innate immune system), as well as for normalization and balancing. the function of the gastrointestinal tract, including after prolonged use of antibiotics, with symptoms of intestinal dysbiosis and inflammatory bowel syndrome.
Alginate impressions of maxillary dental arches of patients will be taken to obtain casts to produce the customized trays. Then, customized trays will be fabricated with no space for reservoir, with 0.9 mm-thick vinyl acetate sheets using the thermoforming process applying a light-cured resin on the casts. Trays will be precisely trimmed completely involving tooth surface (1 mm incisal or occlusal to gingival margin), and the adaptation will be verified on the casts. The trays will be placed over teeth to verify the adaptation in the participants' mouths.
Provided herein are pH -responsive nanovaccines (NVs) that stimulate the immune system. The NVs comprise nano- or micro-particles to which CDN-modified i-motif DNA is attached. When endocytosed within a subject to whom they are delivered, the change in pH to an acidic environment cause the CDNs to be released from the NVs. The CDNs are STING (stimulator of interferon genes) agonists and after their release, they bind to and activate STING, a critical step in stimulating the immune system. The NVs are used e.g. for cancer immunotherapy, to treat viral infections and/or as vaccine adjuvants.
The double-blind, placebo-controlled clinical trial that is carried out in eighty patients who referred to the Department of Periodontology, Isfahan School of Dentistry. Main inclusion criteria were: 1) Patients with moderate to severe chronic periodontitis 2) At least twenty teeth 3) Age over 18 years. Main exclusion criteria were: 1) History of allergy to the macrolide group 2) History of antibiotic therapy within the 4 months ago 3) The lack of patient cooperation. For all patients is initially performed scaling and root planning (SRP). Oral health education is given to all patients. After one month, patients are randomly divided into four equal groups (two test groups and two control groups). Azithromycin(AZM) 250 milligram (mg) capsules, two times a day (bid), for three days will be given to a test group. In the other test group, 1% AZM gel is locally injected into the periodontal pockets in single-root teeth. Placebo capsules with the same dose and frequency will be given to a control group. In the other control group, placebo gel is injected in the same places. Clinical parameters included pocket depth (PD), clinical attachment level (CAL), papillary bleeding index (PBI), and periodontal disease index (PDI), which are recorded at baseline (before SRP), at 1, 2, 3 and 4 months after treatment. Using polymerase chain reaction (PCR), microbiological assessment of the percentage of Porphyromonas gingivalis (P.g) and Actinobacillus actinomycetemcomitans (A.a) are randomly done for 40 patients (10 patients from each group) at baseline and at 3 months after the treatment.
Sparingly soluble complexes of spiramycin or dextromethorphan with cellulose acetate hydrogen phthalate are prepared by reacting the two components in solution in one or more organic solvents, and separating the resulting precipitate.  The polymer is preferably used in molar excess.  The solvents used are acetone methyl ethyl ketone, dioxan, or a 1 : 1 mixture of methanol and benzene.  Other solvents mentioned are: diacetone alcohol; 1 : 1-methanol with acetone; 3 : 1-methanol with acetone; 1 : 1-ethyl acetate with isopropanol; and furfuryl alcohol.  Ethyl cellulose may also be used as a polymer. The complexes are for use as sustained release forms of the particular drugs, and also are useful due to better palatability (see Division A5).ALSO:Solid complexes of spiramycin or dextromethorphan with an acid-reactant cellulose derivative are prepared by reacting solutions, in one or more organic solvents, of the drug and the cellulose derivative, and separating the precipitated complex. The cellulose derivative is preferably cellulose acetate hydrogen phthalate, or ethyl cellulose.  Suitable solvents are acetone, methyl ethyl ketone, diacetone alcohol, dioxane, and furfuryl alcohol, or mixtures thereof.  The complexes are for use in sustained release forms.
Although prostate cancer is a common occurrence among males, the relationship between existing risk prediction models remains unclear. The objective of this hospital-based retrospective study is to investigate the impact of polygenic risk scores (PRSs) on the incidence and prognosis of prostate cancer in the Han Chinese population. A total of 24,778 male participants including 903 patients with prostate cancer at Taichung Veterans General Hospital were enrolled in the study. PRS was calculated using 269 single nucleotide polymorphisms and their corresponding effect sizes from the polygenic score catalog. The association between PRS and the risk prostate cancer was evaluated using Cox proportional hazards regression model. Among the 24,778 participants, 903 were diagnosed with prostate cancer. The risk of prostate cancer was significantly higher in the highest quartile of PRS distribution compared to the lowest (hazard ratio = 4.770, 95% CI = 3.999-5.689, p < 0.0001), with statistical significance across all age groups. Patients in the highest quartile were diagnosed with prostate cancer at a younger age (66.8 ± 8.3 vs. 69.5 ± 8.8, p = 0.002). Subgroup analysis of patients with localized or stage 4 prostate cancer showed no significant differences in biochemical failure or overall survival. This hospital-based cohort study observed that a higher PRS was associated with increased susceptibility to prostate cancer and younger age of diagnosis. However, PRS was not found to be a significant predictor of disease stage and prognosis. These findings suggest that PRS could serve as a useful tool in prostate cancer risk assessment.
The invention relates to an antimicrobial compound zinc bacitracin particle for pigs and a preparation method thereof. The particle comprises the following components by mass: 5-15 parts of zinc bacitracin; 5-10 parts of enrofloxacin; 1-3 parts of Tiandi flavoring; 1-2 parts of aspartame; 20-40 parts of beta-cyclodextrin; 10-20 parts of cane sugar; 5-10 parts of HPMCP; and 20-50 parts of starch. Each bag contains 100 g particles including 5-10 g of zinc bacitracin and 5-10 g of enrofloxacin, and spray drying technology is adopted for coating the raw materials to prepare the finished product. The particle of the invention is uniform, good in fluidity, and consistent in color, has a particle size meeting the specification, and is bright and clean in appearance; zinc bacitracin has good antimicrobial activity to most Gram-positive bacteria; enrofloxacin is a bactericidal wide-spectrum antibacterial drug specially used for animals; the combination of the two drugs enhances the antimicrobial spectrum, and has synergistic effect; the treatment effect is better than that of single-component preparations; the particle is simple in process, good in taste, and suitable for industrial production. The product realizes reasonable combination of the components to enhance the drug effects, which reduces tedious administration of single doses, covers inherent bitter taste of the drugs, and enhances animal compliance to drug administration. The product has the characteristic of simple, convenient, and rapid usage, and is more suitable for pig bacterial disease treatment, growth promotion, and feed utilization rate improvement than other dosage forms.
Including criteria: cervical cancer patients after surgery with big tumor, deep invasion or tumor thrombi in the vascular system, but without lymph invasion, positive surgery margin or parametrium invasion. Patients in this group receive radiation therapy only. radiation therapy regimen: 3D-CRT pelvic radiation, 95%CTV DT 45Gy/25f. Radiation field include tumor bed and regional lymph nodes area. Upper border: branching of abdominal aorta. The radiation fields go down along the iliac vessels (including regions of 7mm out of the iliac vessels) and include the tumor bed region. Lower border: the inferior margin of obturator foramen.
Study participants that meet the inclusion/exclusion criteria for the study may be enrolled in the compassionate use treatment arm. The artificial iris will be implanted in the eye with an iris defect. The fellow eye can be treated 1 month after the primary eye.
AIMS: The optimal antithrombotic therapy to balance the risk of thrombosis and bleeding in patients who undergo transcatheter aortic valve implantation (TAVI) is unknown. This systematic review/network meta-analysis of randomized controlled trials (RCTs) aimed to evaluate the efficacy and safety of different oral anticoagulant (OAC) and antiplatelet regimens in patients post-TAVI.
METHODS AND RESULTS: MEDLINE, Embase, CENTRAL, and ClinicalTrials.gov were searched from inception to April 2023. Co-primary outcomes were all-cause death and major bleeding. We conducted Bayesian network meta-analyses to compare all interventions simultaneously. For each outcome, we generated odds ratios (ORs) with 95% credible intervals using a random-effects model with informative priors, and ranked interventions based on mean surface under the cumulative ranking curve. We included 11 RCTs (n = 6415), including 1 unpublished RCT. Three trials enrolled patients with an indication for an OAC. Overall risk of bias was low or with some concerns. Median age was 81 years. Median follow-up was 6 months. The combination of OAC plus single antiplatelet therapy (SAPT) increased the risk of all-cause death compared with dual antiplatelet therapy (DAPT) (OR 1.78, 95% credible interval 1.15-2.77). No other comparisons for all-cause death were significantly different. For major bleeding, SAPT reduced the risk compared with DAPT, direct-acting OAC, and OAC + SAPT (OR 0.20-0.40), and DAPT reduced the risk compared with OAC + SAPT. SAPT and DAPT ranked best for all-cause death, while SAPT ranked best for major bleeding.
CONCLUSION: In post-TAVI patients, SAPT may provide the optimal balance of reducing thrombotic events while minimizing the risk of bleeding.
Primary immunization: TAK-816 0.5 mL, intramuscular injection, once on Day 1 and every 28 days for 2 intervals (Days 29 and 57). Booster immunization: TAK-816 0.5 mL, intramuscular injection, once, 52 weeks after the third dose of primary immunization.
One Placebo capsule was given TID for the first 21 days. Two placebo capsules were given TID on days 22 till end of study (week 30).
BACKGROUND: In spinal surgery adverse events (AE) and surgical complications (SC) significantly affect patient's outcome and quality of life. The duration of surgery has been investigated in different surgical field as risk factor for complications. The aim of this study is to analyze the correlation between operative time and adverse events in spinal surgery.
METHODS: We retrospectively analyzed data collected prospectively in a cohort of 336 patients surgically treated for spinal diseases of oncological and degenerative origin in a single center, between January 2017 to January 2018. Demographics and clinical data were collected. Adverse events were classified using Spinal Adverse Events Severity System version 2 (SAVES-V2) capture system. Focusing on degenerative patients, bivariate analysis and univariate logistic regression were used to determine the association between operative time and complications.
RESULTS: A total of 105/336 patients experienced an AE related to surgery, respectively 38% in the oncological group and 28% in the degenerative group. The average age at surgery was 60.3 years (SD 17.1) and the mean operative time was 164.8 ± 138 min. A total of 206 adverse events (30 intraoperative, 135 early postoperative and 41 late postoperative AEs) were recorded. Early post-operative complications accounted for the most recorded AEs (55.5% in the oncological group and 73.2% in the degenerative group). Univariate logistic regression analyses confirmed that operative time correlated with increased risk of intra-operative (p-value = 0.0008), early post-operative (p-value < 0.001) and late post-operative (p-value < 0.001) adverse events.
CONCLUSIONS: This study highlights the strong correlation between the occurrence of adverse events in spinal surgery and prolonged operative time and suggests that efforts should be made to minimize the duration of surgical procedures while prioritizing patient's safety, without compromising the technical achievement of the procedure.
PURPOSE:To enable utilization of a space inside an image area by a method wherein data are distributed to peripheral addresses and added as to an address saturated with local concentration of detection of a radioactive material (RI) at the time when image data on an RI image are collected. CONSTITUTION:Position data obtained from detection pass through an address selecting switch 1 and are inputted to an address bus of an image memory 2 and an address of the memory 2 is specified. Data called out for the specified address are inputted to an add one (ADD1) circuit 3 from a data bus and the data to which +1 is added in this circuit 3 are written in the specified address as they are, when the address is not in a state of overflow. In the case when the address is in the state of overflow, a control circuit 4 changes over the switch 1 and a random number addition circuit 5. Thereby a random number is added to the original address data and the same add one operation is executed. Thus, utilization of a space inside an image area relevant to the data is enabled.
Weeks 1-10: exercise program in group. Weeks 11-20: no intervention. Weeks 21-31: no intervention.
A randomised controlled effectiveness pilot trial of the Incredible Years Parents and Babies Program (IY baby)offered as a universal intervention in two municipalities in Denmark. 120 families will be randomised to IY Baby (intervention) og Usual Care (UC- control). Families recruited to the study have infants aged 0-4 months old. All first time mothers in one municipality and all mothers in another municipality are recruited. Outcomes are measured at 20 weeks post baseline and when the child is 18 months old. The aim of this trial is to estimate the effectiveness of the IY Baby program on parent and infant well-being, development and relationship and establish parameters for a definitive trial. In addition, the pilot study will also gather information on parent recruitment and participation to inform future research in this area.